US pharmaceutical company Eli Lilly announced in Shanghai on November 12 that China's National Medical Products Administration (NMPA) had approved its oral GLP-1 drug orforglipron, marketed locally as Muyouda, for long-term weight management in eligible adults. The authorization makes orforglipron China's first approved oral GLP-1 receptor agonist for adult weight management, ahead of Novo Nordisk's oral Wegovy, which remains under regulatory review.
The approval covers adults with obesity and adults who are overweight with at least one weight-related medical condition, alongside dietary changes and increased physical activity. Orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist taken once daily without restrictions on meal timing or water intake.
In Lilly's 72-week Phase 3 ATTAIN-1 trial, which enrolled 3,127 adults with obesity or qualifying overweight conditions without diabetes, patients who continued treatment at the highest orforglipron dose lost an average of 12.4 kilograms, with approximately 40% achieving weight loss of at least 15%. The study assessed different doses against placebo.
Orforglipron received US approval in April 2026 and is marketed there under the Foundayo brand. Novo Nordisk's application for oral Wegovy was accepted by Chinese regulators in August but remains under review. Both companies already compete in China's injectable weight-management market.
Lilly is preparing the commercial launch of orforglipron in China. A launch date and Chinese pricing have not been announced. A separate application for treatment of adults with type 2 diabetes is still under NMPA review.